| Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells D Sarhan, F Cichocki, B Zhang, A Yingst, SR Spellman, S Cooley, ... Cancer research 76 (19), 5696-5706, 2016 | 197 | 2016 |
| Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells MG Angelos, PN Ruh, BR Webber, RH Blum, CD Ryan, L Bendzick, ... Blood, The Journal of the American Society of Hematology 129 (26), 3428-3439, 2017 | 64 | 2017 |
| Metabolic syndrome after hematopoietic cell transplantation: at the intersection of treatment toxicity and immune dysfunction LM Turcotte, A Yingst, MR Verneris Biology of Blood and Marrow Transplantation 22 (7), 1159-1166, 2016 | 35 | 2016 |
| Testing cancer immunotherapy in a human immune system mouse model: correlating treatment responses to human chimerism, therapeutic variables and immune cell phenotypes JA Marín-Jiménez, A Capasso, MS Lewis, SM Bagby, SJ Hartman, ... Frontiers in Immunology 12, 607282, 2021 | 26 | 2021 |
| Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling DM Tufa, AM Yingst, GD Trahan, T Shank, D Jones, S Shim, J Lake, ... Science immunology 5 (53), eaay4218, 2020 | 17 | 2020 |
| Transient expression of GATA3 in hematopoietic stem cells facilitates helper innate lymphoid cell differentiation DM Tufa, AM Yingst, T Shank, S Shim, GD Trahan, J Lake, R Woods, ... Frontiers in Immunology 10, 510, 2019 | 12 | 2019 |
| Prolactin acts on myeloid progenitors to modulate SMAD7 expression and enhance hematopoietic stem cell differentiation into the NK cell lineage DM Tufa, T Shank, AM Yingst, GD Trahan, S Shim, J Lake, R Woods, ... Scientific Reports 10 (1), 6335, 2020 | 9 | 2020 |
| SAHA enhances differentiation of CD34+ CD45+ hematopoietic stem and progenitor cells from pluripotent stem cells concomitant with an increase in hemogenic endothelium SH Shim, D Tufa, R Woods, TD George, T Shank, A Yingst, J Lake, ... Stem Cells Translational Medicine 11 (5), 513-526, 2022 | 5 | 2022 |
| Monocyte subpopulation recovery and outcomes following hematopoietic cell transplantation LM Turcotte, Q Cao, E Krahn, J Curtsinger, AM Yingst, S Cooley, ... Blood, The Journal of the American Society of Hematology 128 (22), 2232-2232, 2016 | 5 | 2016 |
| Therapeutic effect of TRC105 and decitabine combination in AML xenografts J Baik, M Felices, A Yingst, CP Theuer, MR Verneris, JS Miller, ... Heliyon 6 (10), 2020 | 4 | 2020 |
| Proinflammatory cytokine and adipokine levels in adult unrelated marrow donors are not associated with hematopoietic cell transplantation outcomes LM Turcotte, T Wang, MT Hemmer, SR Spellman, M Arora, A Yingst, ... Biology of Blood and Marrow Transplantation 25 (1), 12-18, 2019 | 4 | 2019 |
| 125 Co-opting IL-8 to enhance efficacy of B7H3 CAR T cells against pediatric sarcoma J Lake, K Winkler, A Harrant, A Yingst, K Schaller, E Hoffmeyer, M Larson, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 2 | 2021 |
| ARMING INDUCED PLURIPOTENT STEM CELLS WITH A SYNTHETIC RECEPTOR PROMOTES MASSIVE PRODUCTION OF IMMUNE EFFECTOR CELLS CREATING THE POTENTIAL FOR" OFF-THE-SHELF" IMMUNOTHERAPIES A Yingst, D Vereide, D Jarrell, R Koning, C Arnold, A Romanov, M Murphy, ... Cytotherapy 26 (6), S17, 2024 | | 2024 |
| 366 Synthetic receptor enabled differentiation (ShRED), a novel platform for manufacturing of iPSC-derived cytotoxic innate lymphocytes for “off-the-shelf” cancer immunotherapies S O’Hara, D Vereide, T Rowland, A Yingst, D Jarrell, R Koning, C Arnold, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Generation of synthetic cytokine receptor-induced cytotoxic innate lymphocytes (iCILs) from iPSCs as off-the-shelf cancer therapeutics S O'Hara, T Rowland, R Koning, D Vereide, M Hoffmann, A Yingst, ... Cancer Research 82 (12_Supplement), 547-547, 2022 | | 2022 |
| Gene Editing/Gene Therapies: A SYNTHETIC CYTOKINE RECEPTOR PLATFORM FOR PRODUCING CYTOTOXIC INNATE LYMPHOCYTES AS “OFF-THE-SHELF” CANCER THERAPEUTICS D Vereide, S O’Hara, T Rowland, R Koning, M Hoffmann, A Yingst, ... Cytotherapy 24 (5), S40-S41, 2022 | | 2022 |
| Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction (Vol 22, pg 1159, 2016) LM Turcotte, A Yingst, MR Verneris BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 22 (12), 2286-2286, 2016 | | 2016 |
| Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cell inhibitory acrivities D Sarhan, F Cichocki, B Zhang, A Yingst, SR Spellman, S Cooley, ... EUROPEAN JOURNAL OF IMMUNOLOGY 46, 511-511, 2016 | | 2016 |
